| Patent | Date |
|---|
Anti-hiv Vaccine Antibodies With Reduced Polyreactivity
App 20220289829 - Sievers; Stuart A. ; et al. | 2022-09-15 |
Antibodies Targeting Hiv Escape Mutants
App 20220169707 - Diskin; Ron ; et al. | 2022-06-02 |
Multivalent Carriers And Related Vaccine Compositions
App 20220168414 - Cohen; Alexander A. ; et al. | 2022-06-02 |
Broadly neutralizing anti-HIV-1 antibodies and methods of use thereof
Grant 11,325,966 - Nussenzweig , et al. May 10, 2 | 2022-05-10 |
Hiv Vaccine Immunogens
App 20220031830 - Nussenzweig; Michel ; et al. | 2022-02-03 |
Broadly-Neutralizing ANTI-HIV Antibodies
App 20220002390 - Mouquet; Hugo ; et al. | 2022-01-06 |
Broadly Neutralizing Anti-HIV Antibodies and Epitope Therefor
App 20220002391 - Nussenzweig; Michel ; et al. | 2022-01-06 |
Nucleic acids encoding broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 ENV subunits
Grant 11,155,605 - Nussenzweig , et al. October 26, 2 | 2021-10-26 |
HIV-1 GP120 CD4 binding site antibodies targeting HIV escape mutants
Grant 11,149,081 - Diskin , et al. October 19, 2 | 2021-10-19 |
Broadly-neutralizing anti-HIV antibodies
Grant 11,142,564 - Mouquet , et al. October 12, 2 | 2021-10-12 |
Human Immunodeficiency Virus Neutralizing Antibodies And Methods Of Use Thereof
App 20210230254 - Scheid; Johannes ; et al. | 2021-07-29 |
Human immunodeficiency virus neutralizing antibodies and methods of use thereof
Grant 10,889,633 - Scheid , et al. January 12, 2 | 2021-01-12 |
Broadly Neutralizing Anti-hiv-1 Antibodies And Methods Of Use Thereof
App 20200199203 - Nussenzweig; Michel ; et al. | 2020-06-25 |
Highly Active Agonistic Cd4 Binding Site Anti-hiv Antibodies (haads) Comprising Modified Cdrh2 Regions That Improve Contact With
App 20200165325 - Diskin; Ron ; et al. | 2020-05-28 |
Broadly Neutralizing Anti-HIV Antibodies and Epitope Therefor
App 20200140528 - Nussenzweig; Michel ; et al. | 2020-05-07 |
Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with gp120
Grant 10,590,187 - Diskin , et al. | 2020-03-17 |
Broadly-neutralizing Anti-hiv Antibodies
App 20190345233 - Mouquet; Hugo ; et al. | 2019-11-14 |
Broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 Env subunits
Grant 10,421,803 - Nussenzweig , et al. Sept | 2019-09-24 |
Broadly neutralizing antibody directed against HIV-1 GP140
Grant 10,392,433 - Mouquet , et al. A | 2019-08-27 |
Broadly-Neutralizing ANTI-HIV Antibodies
App 20180282400 - Mouquet; Hugo ; et al. | 2018-10-04 |
Highly Active Agonistic Cd4 Binding Site Anti-hiv Antibodies (haads) Comprising Modified Cdrh2 Regions That Improve Contact With Gp120
App 20180237506 - Diskin; Ron ; et al. | 2018-08-23 |
Antibodies Targeting Hiv Escape Mutants
App 20180230203 - Diskin; Ron ; et al. | 2018-08-16 |
Broadly-neutralizing anti-HIV antibodies
Grant 10,047,146 - Mouquet , et al. August 14, 2 | 2018-08-14 |
Broadly Neutralizing Anti-HIV Antibodies and Epitope Therefor
App 20180171001 - Nussenzweig; Michel ; et al. | 2018-06-21 |
Human Immunodeficiency Virus Neutralizing Antibodies and Methods of Use Thereof
App 20180079800 - Scheid; Johannes ; et al. | 2018-03-22 |
Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120
Grant 9,890,207 - Diskin , et al. February 13, 2 | 2018-02-13 |
Antibodies targeting HIV escape mutants
Grant 9,879,068 - Diskin , et al. January 30, 2 | 2018-01-30 |
Human immunodeficiency virus neutralizing antibodies and methods of use thereof
Grant 9,783,594 - Scheid , et al. October 10, 2 | 2017-10-10 |
Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth
Grant 9,493,549 - Diskin , et al. November 15, 2 | 2016-11-15 |
Crosslinked Anti-hiv-1 Compositions For Potent And Broad Neutralization
App 20160102137 - Bjorkman; Pamela J. ; et al. | 2016-04-14 |
Broadly-Neutralizing Anti-HIV Antibodies
App 20150274813 - Mouquet; Hugo ; et al. | 2015-10-01 |
Human Immunodeficiency Virus Neutralizing Antibodies And Methods Of Use Thereof
App 20140328862 - Scheid; Johannes ; et al. | 2014-11-06 |
Antibodies Targeting Hiv Escape Mutants
App 20140017234 - Diskin; Ron ; et al. | 2014-01-16 |
Anti-hiv Antibodies Having Increased Potency And Breadth
App 20130209454 - Diskin; Ron ; et al. | 2013-08-15 |
Compositions And Methods For Improving Potency And Breadth Of Hiv Antibodies
App 20120288502 - Diskin; Ron ; et al. | 2012-11-15 |
Methods For Creating Or Identifying Compounds That Bind Tumor Necrosis Factor Alpha
App 20120094935 - West; Anthony P. ; et al. | 2012-04-19 |
Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases
Grant 7,374,892 - Feder , et al. May 20, 2 | 2008-05-20 |
Peptides and peptide analogues designed from HFE protein and their uses in the treatment of iron overload diseases
Grant 7,329,650 - Feder , et al. February 12, 2 | 2008-02-12 |
Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases
App 20060287236 - Feder; John N. ; et al. | 2006-12-21 |
Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases
Grant 7,119,170 - Feder , et al. October 10, 2 | 2006-10-10 |
Peptides and peptide analogues designed from HFE protein and their uses in the treatment of iron overload diseases
App 20050282754 - Feder, John N. ; et al. | 2005-12-22 |
Peptides and peptide analogues designed from HFE protein and their uses in the treatment of iron overload diseases
Grant 6,924,265 - Feder , et al. August 2, 2 | 2005-08-02 |
Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases
App 20030073627 - Feder, John N. ; et al. | 2003-04-17 |
Peptides and peptide analogues designed from HFE protein and their uses in the treatment of iron overload diseases
App 20020165162 - Feder, John N. ; et al. | 2002-11-07 |
Peptides and peptide analogues designed from HFE protein and their uses in the treatment of iron overload diseases
Grant 6,284,732 - Feder , et al. September 4, 2 | 2001-09-04 |
Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5
Grant 5,623,053 - Gastinel , et al. April 22, 1 | 1997-04-22 |
| 